



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On November 9, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Karen Karlin

PATENT
Attorney Docket No.: 015280-290110US
Client Ref. No.: E-171-1996/0-US-03
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KLIMPEL *et al.*

Application No.: 09/853,530

Filed: May 9, 2001

For: TARGETING ANTIGENS TO THE
MHC CLASS I PROCESSING
PATHWAY WITH AN ANTHRAX
TOXIN FUSION PROTEIN

Confirmation No. 7146

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed October 9, 2007, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Appl. No. 09/853,530
Amdt. dated November 7, 2007
Reply to Office Action of October 9, 2007

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.